With deceptively similar drug names, these medicines heighten the chances of medication errors, endangering patient safety, particularly in low- and middle-income regions.
Published Oct 30, 2024 | 3:08 PM ⚊ Updated Oct 30, 2024 | 3:08 PM
Dr Parth Sharma, a community physician and public health researcher, delves into the serious risks associated with Look-Alike, Sound-Alike (LASA) medicines in India.
With deceptively similar drug names, these medicines heighten the chances of medication errors, endangering patient safety, particularly in low- and middle-income regions.
Drawing from his article in The Lancet, Dr Sharma explains strategies to reduce these risks and create safer practices within the pharmaceutical industry. Discover how healthcare providers, patients, and policymakers can join forces to avoid these critical errors
Oct 05, 2025
Oct 05, 2025
Sep 26, 2025
Sep 15, 2025
Aug 23, 2025
Jul 07, 2025